The food additive vanillic acid controls transgene expression in mammalian cells and mice by Gitzinger, Marc et al.
The food additive vanillic acid controls transgene
expression in mammalian cells and mice
Marc Gitzinger
1, Christian Kemmer
1, David A. Fluri
1,2, Marie Daoud El-Baba
3,
Wilfried Weber
1,4 and Martin Fussenegger
1,*
1Department of Biosystems Science and Engineering (D-BSSE), ETH Zurich, Mattenstrasse 26, CH-4058 Basel,
Switzerland,
2Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada,
3Universite ´ de Lyon, 43 Boulevard du 11 Novembre 1918, F-69622 Villeurbanne, France,
4Faculty of Biology
and BIOSS Center for Biological Signaling Studies, Albert-Ludwigs-Universita ¨t Freiburg, Scha ¨nzlestrasse 1,
D-79104 Freiburg, Germany
Received August 27, 2010; Revised November 27, 2011; Accepted November 30, 2011
ABSTRACT
Trigger-inducible transcription-control devices
that reversibly fine-tune transgene expression in
response to molecular cues have significantly
advanced the rational reprogramming of mamma-
lian cells. When designed for use in future gene-
and cell-based therapies the trigger molecules
have to be carefully chosen in order to provide
maximum specificity, minimal side-effects and
optimal pharmacokinetics in a mammalian organ-
ism. Capitalizing on control components that
enable Caulobacter crescentus to metabolize
vanillic acid originating from lignin degradation
that occurs in its oligotrophic freshwater habitat,
we have designed synthetic devices that specifically
adjust transgene expression in mammalian cells
when exposed to vanillic acid. Even in mice trans-
gene expression was robust, precise and tunable in
response to vanillic acid. As a licensed food additive
that is regularly consumed by humans via flavoured
convenience food and specific fresh vegetable
and fruits, vanillic acid can be considered as a
safe trigger molecule that could be used for diet-
controlled transgene expression in future gene-
and cell-based therapies.
INTRODUCTION
Synthetic control devices providing precise expression
ﬁne-tuning of mammalian transgenes in response to
molecular cues have been fundamental for functional
genomic research (1), biopharmaceutical manufacturing
of difﬁcult-to-express protein therapeutics (2–4), drug dis-
covery (5,6), tissue engineering (7–9), the design of
complex synthetic gene networks (10–13), prototypic
gene therapy applications (9,14,15) and the design of func-
tional materials (16). Most of the currently available mam-
malian transgene-control devices share a common design
principle, which ensures that the basic transcription con-
trollers are compatible and could be assembled to higher
order control networks (10–13). The basic control switches
consist of synthetic transcription factors, prokaryotic
response regulators fused to either a transactivation or
a transsilencing domain, which bind and induce or
repress chimeric promoters containing speciﬁc oper-
ator sites (17–19). Transcription can be ﬁne-tuned by a
speciﬁc trigger compound that modulates the promoter
afﬁnity of the chimeric transcription factors in a
dose-dependent manner (20–24).
Besides optimal regulation performance the character-
istics of the trigger molecule is of key importance when
control circuits are designed for future gene- and
cell-based therapies. Therefore, the latest generation
of transgene control systems considers inducer molecules
with minimal potential side effects such as those
derived from endogenous metabolites (15,25–27) or
physiologically inert molecules, such as licensed cosmetic
compounds (28).
Vanillic acid is the oxidized form of vanillin and found
at high concentrations in vanilla beans (29,30) and in
Angelica sinensis, a plant used in traditional Chinese
medicine (31). Vanillic acid has been associated with a
variety of pharmacologic activities such as inhibiting
snake venom activity (32,33), carcinogenesis (34), apop-
tosis (35,36) and inﬂammation (37) but it has become
most popular for its pleasant creamy odour that is
widely used in fragrances and licensed as a food additive
(FAO/WHO Expert Committee on Food Additives,
JECFA no. 959). Vanillic acid is also one of the main
metabolites found in humans after consumption of green
tee infusions (38). Overall, vanillic acid has all it takes to
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switches designed for future therapeutic applications.
Caulobacter crescentus is a Gram-negative, oligotrophic
freshwater bacterium that plays an important role in the
carbon cycle by disposing of the soluble phenolic inter-
mediates such as vanillic acid that result from fungal oxi-
dative cleavage of lignin originating from decaying
vascular plant material (39–41). Caulobacter crescentus
can utilize vanillic acid as its sole carbon source by
metabolizing it to protocatechuate and then to succinyl-
CoA as well as acetyl-CoA, which is converted to meta-
bolic energy in the citric acid cycle (42,43). Unless
C. crescentus comes across vanillic acid the corresponding
monooxygenase encoded by the VanAB gene cluster
remains shut down as the transcriptional repressor
VanR binds a distinct perfect inverted repeat operator
(VanO; ATTGGATCCAAT) upstream of the vanAB
promoter region (43). However, vanillic acids binds
VanR and derepresses the metabolic pathway (43–47).
Capitalizing on the C. crescentus vanillic acid-responsive
transcriptional repressor VanR, we engineered different
variants of a synthetic vanillic acid-responsive mammalian
expression system (VAC) that show excellent regulation
performance in mammalian cells as well as in mice
receiving vanillic acid.
MATERIALS AND METHODS
Plasmid construction
Table 1 lists all the plasmids used in this study and
provides detailed information about their construction.
Using the basic local alignment search tool (BLAST) all
of our promoter and operator sequences were shown to be
free of binding sites speciﬁc from mammalian proteins.
Cell culture
Wild-type Chinese hamster ovary cells (CHO-K1, ATCC:
CCL-61) and their derivatives were cultivated in standard
medium: ChoMaster HTS (Cell Culture Technologies,
Gravesano, Switzerland) supplemented with 5% (v/v)
foetal calf serum (FCS, PAN Biotech GmbH,
Aidenbach, Germany, Cat. No. 3302, Lot No. P251110)
and 1% (v/v) penicillin/streptomycin solution (Biowest,
Nuaille ´ , France, Cat. No. L0022-100, Lot No.
S07497L0022). Human embryonic kidney cells
(HEK293-T, ATCC: CRL-11268), human cervical carcin-
oma cells (HeLa, ATCC: CCL-2), African green monkey
kidney cells (COS-7, ATCC: CRL-1651), baby hamster
kidney cells (BHK-21, ATCC: CCL10), human ﬁbrosar-
coma cells (HT-1080, ATCC: CCL-121) and mouse ﬁbro-
blasts (NIH/3T3, ATCC CRL-1658) were cultivated in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% FCS and 1% penicillin/streptomycin
solution. All cell lines were cultivated at 37 Ci na
humidiﬁed atmosphere containing 5% CO2. Viable cell
numbers were determined using a Casy Cell Counter
and Analyser Model TT (Roche Diagnostics GmbH,
Basel, Switzerland).
Transfection
The CHO-K1 cells were transiently transfected using
0.5mg of total plasmid DNA (equimolar plasmid ratios
were used for co-transfections) according to an optimized
calcium phosphate-based protocol (48). As for other cell
lines the transfection efﬁciency was tuned to reach 35%±
5% as determined by parallel transfections using
pd2EYFP (Clontech, Mountain View, CA, USA) (15).
In brief, 50000 CHO-K1 cells were seeded into each well
of a 24-well plate and cultured overnight. The plasmid
DNA was then diluted to a total volume of 25ml with
0.5M CaCl2 solution, which was mixed with 25ml
2 HBS solution (50mM HEPES/280mM NaCl/1.5mM
Na2HPO4, pH 7.1). This mixture was incubated for 15min
at room temperature before the precipitates were directly
added into the well and centrifuged onto the cells (5min at
1200g). After 3h, the cells were treated with 0.5ml
glycerol solution (ChoMaster HTS medium containing
15% glycerol) for 60s. After washing once with
phosphate-buffered saline (PBS, Dulbecco’s phosphate-
buffered saline; Invitrogen, Basel, Switzerland, Cat. No.
21600-0069), the cells were cultivated in 0.5ml standard
ChoMaster HTS medium in the presence or absence of
different concentrations of vanillic acid or its derivatives.
For the transient transfection of BHK-21, COS-7 and
HEK-293 cells, a plasmid DNA-Ca2PO4 precipitate was
prepared and applied to the 50000 cells cultivated per well
of a 24-well plate, as described above. The HEK-293 and
COS-7 cells were washed once with PBS after 3h incuba-
tion with the DNA-Ca2PO4 precipitate and subsequently
cultivated in standard DMEM, while BHK-21 and HeLa
cells were incubated overnight with the precipitates and
then cultivated in DMEM after being washed once with
PBS. The HT-1080 and NIH/3T3 cell lines were trans-
fected with Fugene
TM 6 (Roche Diagnostics AG, Basel,
Switzerland, Cat. No. 11814443001) according to the
manufacturer’s protocol and cultivated in the cell culture
medium speciﬁed above. After transfection, all cells were
cultivated in DMEM supplemented with different concen-
trations of vanillic acid and reporter protein levels were
proﬁled 48h after transfection, unless indicated otherwise.
Construction and characterization of the stable cell line
CHO-VAC
The CHO-VAC12 cell line, transgenic for vanillic
acid-controlled SEAP expression, was constructed by
sequential co-transfection and clonal selection of (i)
pMG250 (PSV40-VanA1-pA) and pSV2neo (Clontech,
Cat. No. 6172-1) at a ratio of 20:1 to result in the cell
line CHO-VanA, (ii) CHO VanA was subsequently
co-transfected with pMG252 (P1VanO2-SEAP-pA) and
pPur (Clontech, Cat. No. 6156-1) (ratio of 20:1), and the
resulting double-transgenic cell line CHO-VAC12,
showing vanillic acid-responsive SEAP production, was
chosen after clonal selection. To assess the vanillic
acid-mediated transgene regulation characteristics,
100000 cells/ml of CHO-VAC12 were cultivated for 48h
in standard ChoMaster HTS medium supplemented with
increasing concentrations of vanillic acid, ranging from 0
to 1000mM. Reversibility of the vanillic acid-mediated
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(100000 cells/ml) for 144h while alternating vanillic acid
concentrations from 0 to 500mM every 48h.
Quantiﬁcation of reporter gene expression
Production of the human placental secreted alkaline
phosphatase (SEAP) and the heat-stable Bacillus
stearothermophilus-derived secreted a-amylase was
quantiﬁed as described previously (49,50).
Inducer compounds: vanillic acid and its derivatives
The following were prepared as 50mM stock solutions in
70% (v/v) EtOH and adjusted to pH 7 using 2.5M NaOH
when required: 2-vanillic acid (2-hydroxy-3-methoxy
benzoic acid, ABCR, Karlsruhe, Germany, Cat. No.
AB177480), 2-vanillin (2-hydroxy-3-methoxybenzal
dehyde, ABCR, Cat. No. AB117268), acetovanillone
(40-hydroxy-30-methoxyacetophenone, ABCR, Cat.
No. AB125832), benzaldehyde (Acros, Geel, Belgium,
Cat. No. 378361000), benzoic acid (ABCR, Cat. No.
AB113879), benzyl acetate (ABCR, Cat. No. AB131641),
benzyl alcohol (ABCR, Cat. No. AB171491), ethyl-
vanillate (ABCR, Cat. No. AB178082), ethyl-vanillin
(3-ethoxy-4-hydroxybenzaldehyde, ABCR, Cat. No.
AB126381), eugenol (ABCR, Cat. No. AB111881),
homovanillic acid (Sigma, St Louis, MO, USA, Cat. No.
H1252-1G), isovanillic acid (3-hydroxy-4-methoxybenzoic
acid, ABCR, Cat. No. AB117271), isovanillin
(3-hydroxy-4-methoxybenzaldehyde, ABCR, Cat. No.
AB117270), methyl-vanillate (ABCR, Cat. No.
AB132603), protocatechualdehyde (3,4-dihydroxy
benzaldehyde, ABCR, Cat. No. AB110948) and vanillin
(ABCR, Cat. No. AB117415). Vanillic acid (Fluka, Buchs,
Switzerland, Cat. No. 94770-10G) was prepared as a
50mM stock solution in water and adjusted to pH 7
with 2.5M NaOH. All solutions were used at a ﬁnal con-
centration of 250mM unless otherwise indicated.
Tetracycline (Sigma, Cat. No. T7660) was prepared as
a 1mg/ml stock solution in H2O, and erythromycin
(Fluka, Cat. No. 45673) as a stock solution of 1mg/ml
in ethanol. Both antibiotics were used at a ﬁnal concen-
tration of 2mg/ml.
In vivo methods
The CHO-K1 cells, engineered for vanillic acid-controlled
SEAP expression (CHO-VAC12) and for constitutive
SEAP expression [CHO-SEAP18 (51)], were encapsu-
lated in 400mm alginate-poly-(L-lysine)-alginate beads
(400 cells/capsule) using an Inotech Encapsulator
Research IE-50R (EncapBioSystems Inc., Greifensee,
Switzerland) according to the manufacturer’s instructions
and the following parameters: 0.2mm nozzle, 20ml
syringe at a ﬂow rate of 405 U, nozzle vibration frequency
of 1116Hz and 950V for bead dispersion. Female OF1
mice (oncins France souche 1, Charles River
Laboratories, France; n=8 for all experiments) were im-
planted intraperitoneally with 700ml of FCS-free
ChoMaster HTS containing 4 10
6 encapsulated
CHO-VAC12 cells. Control mice were implanted with
microencapsulated CHO-K1 or CHO-SEAP18. One hour
after implantation, vanillic acid (50mg/ml in PBS, pH7)
was administered twice daily by injection for the next three
days at doses ranging from 0 to 500mg/kg. After 72h, the
mice were sacriﬁced, blood samples were collected
retroorbitally and SEAP levels were quantiﬁed in the
serum, which was isolated using a microtainer SST tube
according to the manufacturer’s instructions (Beckton
Dickinson, Plymouth, UK, Cat. No. 365968). All the ex-
periments involving mice were performed according to the
directives of the European Community Council (86/609/
EEC), approved by the French Republic (No. 69266310)
and performed by Marie Daoud El-Baba at the Universite ´
de Lyon, F-69622 Villeurbanne, France.
Preparation of mouse organ extracts
Organs (kidney, liver, lung, muscle) of female OF1 mice
were homogenized in PBS (1:2 (v/v); organ:PBS) using an
IKA T18 basic ULTRA-TURRAX disperser (IKA
GmbH, Staufen, Germany), mixed with 10% (v/v) hydro-
chloric acid (Fluka, Cat. No. 35327) for 5s using a vortex
and incubated with 6ml ethyl acetate (Sigma Cat. No.
270989) at 4 C while shaking overnight to extract
vanillic acid from the tissue samples. As positive control
a liver and a kidney sample were spiked with 100mlo fa
50mM vanillic acid stock solution prior to tissue hom-
ogenization. The tissue homogenates were then
centrifuged for 10min at 6000g and 4 C and the super-
natants were dried using a rotary evaporator (Rotavapor
R-215, Bu ¨ chi Labortechnik AG, Flawil, Switzerland).
Dried samples were re-suspended in 300ml methanol
(Sigma, Cat. No. 322415), dried again using an
Eppendorf concentrator (Eppendorf concentrator plus,
Vaudaux-Eppendorf, Scho ¨ nenbuch, Switzerland, Cat.
No. 5305 000.304) and were ﬁnally resuspended in 300ml
dimethyl sulfoxide (DMSO, Sigma, Cat. No. D4540). 5ml
of organ extracts were mixed with 500ml ChoMaster
HTS and added to CHO-K1 cultures containing the
VACOFF or the VACON expression systems.
RESULTS
Design of vanillic acid-responsive mammalian
transcription-control devices
Using the basic parts that control vanillic acid metabolism
in C. crescentus, the transcriptional repressor VanR and
its target operator VanO, we have designed two different
vanillic acid-responsive transcription-control devices that
either induce (VACON) or repress (VACOFF) target
gene transcription in the presence of the food additive
vanillic acid.
The VACON system was assembled by fusing VanR
C-terminally to the human Krueppel-associated box
[KRAB; (52)] domain to generate a mammalian trans-
silencer (VanA4) that binds and represses a chimeric
promoter (PVanON8) consisting of a constitutive human
cytomegalovirus immediate early promoter (PhCMV) con-
taining an octameric VanO operator module (VanO8)
immediately downstream. Vanillic acid triggers the
release of VanA4, which derepresses PVanON8 and results
in PhCMV-driven transgene expression (Figure 1A). When
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(PVanON8-SEAP-pA) into CHO-K1 expression of
SEAP was insigniﬁcant (1.70±0.23U/L). However,
when adding increasing concentrations of vanillic acid
(0–250mM) SEAP expression was dose-dependently
induced up to a level of 25.3±2.08U/l (Figure 1B).
The VACOFF system was designed by fusing VanR
C-terminally to the Herpes simplex virus transactivation
domain VP16 to generate a chimeric transcription factor
(VanA1) that binds to two VanO-operator sequences
separated only by an Eco47III restriction site (VanO2,
50-ATTGGATCCAATagcgctATTGGATCCAAT-30,
VanO operator upper case) and activates a 30-placed
minimal version of PhCMV (PhCMVmin)( P 1VanO2). Vanillic
acid triggers the release of VanA1, which inactivates
P1VanO2 and shuts transgene expression down (Figure
1C). Co-transfection of pMG250 (PSV40-VanA1-pA), and
pMG252 (P1VanO2-SEAP-pA) into CHO-K1 resulted in
high SEAP expression levels (20.3±0.5U/l) comparable
to an isogenic constitutive SEAP control vector
(pSEAP2-Control; PSV40-SEAP-pA) (33.9±0.2U/l).
However, when adding increasing concentrations of
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Figure 1. Design and validation of the VACON and VACOFF systems. (A and B) Diagram and functionality of the VACON system. (A) VanR was
fused to the KRAB transrepressor domain, a human Krueppel-associated box protein, resulting in VanA4 (VanR-KRAB), which was expressed by
the constitutive human cytomegalovirus immediate early promoter (PhCMV) (pCK189). The vanillic acid-inducible promoter PVanON8 harbors eight
VanO operator sites immediately 30 of a constitutive Simian virus 40 promoter (PSV40) that was set to drive the human placental secreted alkaline
phosphatase (SEAP) (pCK191). OFF status: VanA4 is constitutively expressed and, in the absence of vanillic acid (–VAC), binds to PVanON8 and
represses SEAP expression. ON status: in the presence of vanillic acid (+VAC), VanA4 is released from PVanON8 which fully induces SEAP expres-
sion. (B) CHO-K1 cells were transiently transfected with pCK189 (PSV40-VanA4-pA) and pCK191 (PVanON8-SEAP-pA) and SEAP-expression proﬁles
were assessed 48h after cultivation of the cells in medium containing different concentrations of vanillic acid (0–250mM). (C and D) Diagram and
functionality of the VACOFF system. (C) VanR was fused to the VP16 transactivation domain of the Herpes simplex virus, resulting in VanA1
(VanR-VP16), which was expressed by the constitutive Simian virus 40 promoter (PSV40) (pMG250). The vanillic acid-responsive promoter P1VanO2
contains two VanO operator sites (ATTGGATCCAATAGCGCTATTGGATCCAAT; VanR binding sites in italics) immediately 50 of a minimal
human cytomegalovirus immediate-early promoter (PhCMVmin), which was set to drive the human placental secreted alkaline phosphatase (SEAP)
(pMG252). ON status: VanA1 is constitutively expressed and, in the absence of vanillic acid (–VAC), binds to P1VanO2 and activates SEAP expres-
sion. OFF status: in the presence of vanillic acid (+VAC), VanA1 is released from P1VanO2 which shuts down SEAP expression. (D) CHO-K1 cells
were transiently transfected with pMG250 (PSV40-VanA1-pA) and pMG252 (P1VanO2-SEAP-pA) and SEAP-expression proﬁles were assessed 48h
after cultivation of the cells in medium containing different concentrations of vanillic acid (0–250mM).
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down to almost complete repression (0.31±0.01U/l)
(Figure 1D).
In order to assess the impact of vanillic acid on mam-
malian cell cultures, we exposed CHO-K1 cells, transiently
transfected with pSEAP2-control (PSV40-SEAP-pA), to
increasing concentrations of vanillic acid (0–1000mM)
and proﬁled SEAP production as well as viable cell
numbers for 48h. The observation that SEAP levels and
cell numbers remained equally high at all vanillic acid
concentrations (0mM: 33.9±0.17U/l, 9.08±0.84
(10
6cells/ml); 1000mM: 35.4±1.74U/l, 9.22±0.9
(10
6cells/ml)) indicates that the licensed food additive
has no obvious impact on cell physiology below a con-
centration of 1mM. This observation was conﬁrmed
by scoring the viability of CHO-K1 and HEK-293
exposed to regulation-effective vanillate concentrations
(Supplementary Figure S1). Since the basic VACOFF
system shows tighter regulation performance, no epigen-
etic imprinting compared to the KRAB-containing
VACON design (53,54) and is the conﬁguration of choice
for the assembly of advanced synthetic multi-control gene
networks (13), we chose to use VACOFF in all follow-up
studies.
VACOFF-controlled transgene expression in various
mammalian cell lines
Versatility of the VACOFF-system was assessed
by co-transfection of pMG250 (PSV40-VanA1-pA) and
pMG252 (P1VanO2-SEAP-pA) into different rodent,
monkey and human cell lines followed by cultivation for
48h in the presence (+) and absence (–) of 250mM
vanillic acid (BHK-21: –, 0.52±0.02U/l;+, 0.05±
0.01U/l; COS-7: –, 17.95±0.55U/l; +, 0.45±0.02U/l;
HEK-293: –, 484.96±54.24U/l; +, 20.85±1.24U/l;
HeLa: –, 7.89±0.99U/l;+, 1.38±0.11U/l; HT-1080: –,
0.65±0.11U/l; +, 0.07±0.01U/l; and NIH/3T3: –,
7.41±0.16U/l; +, 0.28±0.12U/l). SEAP production
levels indicated that VACOFF-controlled transgene regula-
tion was functional in all tested cell lines, suggesting a
broad applicability of this control technology.
Optimizing the VACOFF system I—assessment of
promoter variants containing varying numbers of VanO
operator modules
Altering the number of operator modules in front of an
inducible minimal promoter impacts the regulation per-
formance regarding (i) maximal expression levels, as an
increasing number of operator sites can recruit more
transactivators and (ii) basal expression of the system’s
repressed state, as more transactivators have to be
released from an increasing number of operator sites
(27,55). To evaluate the optimal number of VanO-
operator sites for VACOFF-controlled gene regulation,
we constructed VanA1-responsive promoter variants har-
bouring either one (pMG262, P1VanO1-SEAP-pA; P1VanO1,
NruI-VanO-0bp-PhCMVmin), two (pMG252, P1VanO2-
SEAP-pA; P1VanO2, NruI-VanO-Eco47III-VanO-
0bp-PhCMVmin), three (pMG263, P1VanO3-SEAP-pA;
P1VanO3, NruI-VanO-Eco47III-VanO-6bp-VanO-0bp-
PhCMVmin) or four (pMG264, P1VanO4-SEAP-pA;
P1VanO4, NruI-VanO-Eco47III-VanO-6bp-VanO-Eco
47III-VanO-0bp-PhCMVmin) operators immediately 50 of
the minimal promoter. Co-transfection of corresponding
SEAP expression vectors harbouring the different
promoter variants with pMG250 (PSV40-VanA1-pA) into
CHO-K1, HEK-293 and BHK-21 cells and scoring of
SEAP levels 48h after cultivation in the presence and
absence of 250mM vanillic acid revealed their transcrip-
tional performances. In all cell lines, it was observed that
an increasing number of operator modules resulted in
higher maximum expression levels but also in higher
basal expression of the repressed status. The dimeric
promoter conﬁguration (pMG252, P1VanO2-SEAP-pA)
resulted in the best regulation performance with a
72-fold induction factor in CHO-KI cells and 23-fold in
HEK-293 cells, while the trimeric promoter set-up showed
the best performance in BHK-21 cells with a ON/OFF
control factor of 11 (Figure 2A–C).
Optimizing the VACOFF system II—engineering of
different vanillic acid-dependent transactivator variants
Basal and maximum expression of synthetic mammalian
gene regulation systems can be inﬂuenced by the kind of
mammalian transactivation domain, which is fused to the
bacterial DNA-binding protein (19,56). We have therefore
evaluated different transactivation domains by designing
vectors containing VanR fused to the Herpes simplex-
derived VP16 domain (pMG250, PSV40-VanA1-pA;
VanA1,VanR-VP16), the human nuclear factor kappa B
(NF-B) -derived transactivation domain p65 (pMG256,
PSV40-VanA2-pA; VanA2, VanR-p65) or the transactiva-
tion domain of the human E2F transcription factor
4 (E2F4) (pMG257, PSV40-VanA3-pA; VanA3,
VanR-E2F4). Co-transfection of corresponding
transactivator-encoding expression vectors with pMG252
(P1VanO2-SEAP-pA) into CHO-K1, HEK-293, BHK-21,
HT-1080 and HeLa cells and scoring of SEAP levels
48h after cultivation in the presence and absence of
250mM vanillic acid revealed the performances of the in-
dividual transactivators. The basal as well as maximum
expression levels varied considerably amongst the differ-
ent transactivators. In general, E2F4 showed the weakest
maximum expression levels in all tested cell lines and
could therefore not compete with the best-in-class regula-
tion performance of VP16 and p65. In CHO-K1, VP16
exhibited the highest maximum expression paired with
the lowest leakiness, making it the transactivator of
choice for this cell line (Table 2). Peak expression in
HEK-293 cells was achieved by p65, although the high
basal expression again rendered VP16 the best choice in
terms of the regulation factor. In HeLa cells, only VP16
provided signiﬁcant transactivation, while in BHK-21 and
HT-1080 cells p65 offered the best performance (Table 2).
Due to their cell-type speciﬁcity, their graded maximum
transcription initiation capacities and their basal expres-
sions in the repressed status, the three transactivators
offered a selection of different expression windows and
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Optimizing the VACOFF system III—promoter variants
that differ in the distance between VanO operator modules
and the minimal promoter
Maximum transcription levels and minimum leakiness are
not only inﬂuenced by the number of operator modules
recruiting the transactivators, but also by the relative
spacing of the operator modules to the minimal
promoter and the resulting torsion angle of the
operator-bound transactivator (57,58). To further assess
the optimal design of PVanO conﬁgurations, we engineered
spacers of 2bp increments between the two VanO modules
(VanO2) and PhCMVmin, resulting in SEAP expression
vectors, isogenic to pMG252 (P1VanO2-SEAP-pA) which
harbours the default 18bp between VanO2 and
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Figure 2. Validation of vanillic acid-responsive promoter variants containing different numbers of VanO operator modules. Vectors encoding SEAP
expression driven by a vanillic acid-responsive promoter harbouring monomeric (pMG262), dimeric (pMG252), trimeric (pMG263) or tetrameric
(pMG264) operator modules were co-transfected with pMG250 (PSV40-VanA1-pA) into (A) CHO-K1, (B) HEK-293 and (C) BHK-21 cells and SEAP
production was scored after cultivation for 48h in the presence and absence 250mM vanillic acid.
Table 2. Combinatorial proﬁling of different VACOFF transactivators and promoters in various cell types
SEAP Production (U/l)
pMG252/pMG250 (VP16) pMG252/pMG256 (p65) pMG252/pMG257 (E2F4)
Vanillic acid (250mM)   +      +
BHK-21 0.52±0.02 0.05±0.01 1.22±0.05 0.08±0.01 0.24±0.05 0.04±0.01
CHO-K1 27.06±0.16 0.59±0.01 26.31±1.38 2.13±0.17 15.02±0.44 1.35±0.13
HEK-293 484.96±54.24 20.85±1.24 1032.46±63.34 54.2±4.00 203.79±36.96 12.79±2.12
HeLa 7.89±0.99 1.38±0.11 1.37±0.06 1.49±0.08 1.49±0.12 1.44±0.07
HT-1080 0.65±0.11 0.07±0.01 1.28±0.15 0.13±0.02 0.13±0.03 0.02±0.00
SEAP production was quantiﬁed 48h after transient co-transfection of pMG252 (P1VanO2-SEAP-pA) and either pMG250 (PSV40-VanA1-pA;
VanR-VP16), pMG256 (PSV40-VanA2-pA; VanR-p65) or pMG257 (PSV40-VanA3-pA; VanR-E2F4).
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PhCMVmin), pMG266 (P3VanO2, VanO2-4bp-PhCMVmin),
pMG267 (P4VanO2, VanO2-6bp-PhCMVmin), pMG268
(P5VanO2, VanO2-8bp-PhCMVmin) and pMG269 (P6VanO2,
VanO2-10bp-PhCMVmin) contain an additional 2, 4, 6, 8
or 10bp between VanO2 and PhCMVmin. Any of the
vectors comprising the vanillic acid-responsive promoter
variants were co-transfected with pMG250 (PSV40-VanA1-
pA), pMG256 (PSV40-VanA2-pA) or pMG257 (PSV40-
VanA3-pA) into CHO-K1 cells to evaluate the optimal
promoter conﬁguration independently of the
transactivator variant. The expression of SEAP was
scored 48h after cultivation of the transfected cells in
media containing 0, 50 or 250mM of vanillic acid
(Figure 3A–C). Generally, P1VanO2 exhibited the best regu-
lation performance in terms of maximal expression and
minimal leakiness. The promoter variants with 2, 4 and
10bp spacers (pMG265, pMG266 and pMG269) showed
expression performances, which were comparable to the
best-in-class conﬁguration harbouring no spacer
(pMG252). However, pMG267 and pMG268 (6 and
8bp increments) resulted in a much lower maximal expres-
sion. All promoter variants displayed similar expression
proﬁles for all VanA transactivator variants, implying
that chimeric promoters and transactivators can be inde-
pendently optimized.
Design of an autoregulated version of the vanillic acid-
responsive VACOFF expression system
Besides the conventional two-vector design, consisting of
a plasmid for constitutive expression of a transactivator
and a second vector encoding the responsive promoter
that drives transcription of the gene of interest, we also
designed an autoregulated single-vector set-up for vanillic
acid-controlled transgene expression. The autoregulated
design consists of P1VanO2 producing a dicistronic tran-
script sequentially encoding SEAP and VanA1 preceded
by a polioviral internal ribosome entry site (IRESPV)
(P1VanO2-SEAP-IRESPV-VanA1-pA). Whereas SEAP is
translated in a classical cap-dependent manner, transla-
tion initiation of VanA1 is mediated by IRESPV. Such
an autoregulated conﬁguration represents the most
compact transgene-control design, is convenient for
overcoming undesired expression variations in transient
transfections and is useful for the design of noise-resistant
gene networks (59). Transfection of pMG270 (P1VanO2-
SEAP-IRESPV-VanA1-pA) into CHO-K1 cells started
leaky expression of VanA1, which then in an
autoregulated feedback initiated full activation of the
VanA-responsive promoter P1VanO2 to reach maximum
levels of SEAP production and co-cistronic expression of
VanA1. When 250mM vanillic acid was added to the
culture, the autoregulated induction was interrupted and
SEAP expression remained in the fully repressed state
(0mM vanillic acid: 9.58±0.29U/l; 250mM vanillic acid:
0.30±0.04U/l). The SEAP levels for this experiment were
proﬁled after 48h.
Expression kinetics, adjustability and reversibility of
VACOFF-controlled transgene expression in a stably
transgenic CHO-K1 cell line
Detailed characterization of long-term expression, adjust-
ability and reversibility of the VACOFF system requires the
creation of a stable cell line. We therefore established
stable CHO-K1-derived VACOFF-containing cell lines
(CHO-VAC) by sequential transfection of pMG250
(PSV40-VanA1-pA) and pMG252 (P1VanO2-SEAP-pA) and
subsequent clonal selection. The expression of SEAP was
scored for ﬁve randomly chosen single clones after culti-
vation for 48h in the presence and absence of 500mM
vanillic acid. All clones showed similar basal expression,
but varied substantially in their maximum SEAP expres-
sion levels (Figure 4A). With a regulation factor of 92-fold
repression, CHO-VAC12 showed the best regulation per-
formance out of the ﬁve single clones. Furthermore,
CHO-VAC12 revealed precise adjustability according to
the level of vanillic acid administered to the medium
(Figure 4B) and displayed unchanged maximal expression
and repression levels in long-term cultures of up to 90 days
(Day 0, ON: 109.13±3.80U/l, OFF: 1.19±0.04U/l;
Day 90, ON: 104.36±5.75U/l, OFF: 1.45±0.09U/l).
Besides excellent adjustability, rapid response kinetics
and reversibility are essential for high-performance mam-
malian gene regulation systems. When cultivating
CHO-VAC12 for 72h, the system showed exponential
SEAP expression kinetics without vanillic acid in the
medium, whereas upon addition of 500mM of the trigger
compound, SEAP expression levels did not signiﬁcantly
exceed the background levels (Figure 4C). Full reversibil-
ity of the VACOFF-system was monitored when cultivating
CHO-VAC12 for 144h while alternating the vanillic
acid concentration every 48h between 0 and 500mM
(Figure 4D).
Compatibility of the VACOFF-system with other transgene
regulation systems
The broad applicability of mammalian transgene regula-
tion systems within complex synthetic gene networks is
also determined by their ability to function
interference-free alongside other regulation systems that
capitalize on different inducers (11,12,60,61). To assess
this important requirement, we transiently transfected
CHO-VAC12 with the established components of the
tetracycline- (TETOFF) (21) or the erythromycin- (EOFF)
(18) responsive expression systems. Both, the TETOFF
(pSAM200, PSV40-tTA-pA; pBP99, PhCMV*-1-SAMY-pA)
and the EOFF (pWW35, PSV40-ET1-pA; pBP100, PETR3-
SAMY-pA) systems drove the expression of the
heat-stable Bacillus stearothermophilus-derived secreted
a-amylase [SAMY, (50)] under a tetracycline- or an
erythromycin-responsive promoter, respectively. The
levels of SEAP and SAMY were scored 48h after trans-
fection and cultivation of the CHO-VAC12 cell line in the
presence or absence of the different inducers (500mM
vanillic acid/2mg/ml tetracycline/2mg/ml erythromycin)
and a completely compatible, interference free and fully
functional regulation performance in the same
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Figure 3. Combinatorial validation of the VACOFF system in different transactivator and promoter conﬁgurations. VACOFF transactivators em-
ploying different transactivation domains (A: VanA1, VanR-VP16; pMG250) (B: VanA2, VanR-p65; pMG256) (C: VanA3, VanR-E2F4; pMG257)
were co-transfected with different vanillic acid-responsive promoter variants containing 0 (P1VanO2; pMG252), 2 (P2VanO2; pMG265), 4 (P3VanO2;
pMG266), 6 (P4VanO2; pMG267), 8 (P5VanO2; pMG268) and 10 (P6VanO2; pMG269) base-pair linkers between VanO and the minimal promoter into
CHO-K1 cells. All promoter variants drove SEAP expression and the production was proﬁled 48h after cultivation of the cells in media containing
different concentrations of vanillic acid (0, 50 and 250mM).
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TETOFF and EOFF systems (Table 3).
Speciﬁcity of the VACOFF system
VanR plays a key role in controlling lignin biodegradation
of C. crescentus. One of the commonly produced com-
pounds in this pathway is vanillic acid, but closely
related compounds were also suggested as being able to
directly interact with VanR (43). To assess the speciﬁcity
of the VAC system and the capability of isomeric com-
pounds of vanillic acid to interact with the synthetic
mammalian-adapted VanA1 transactivator, we cultivated
CHO-VAC12 for 48h in media containing 0, 250 and
500mM of a comprehensive set of compounds closely
related to vanillic acid (2-vanillic acid, 2-vanillin,
acetovanillone, benzaldehyde, benzoic acid, benzyl
acetate, benzyl alcohol, ethyl-vanillate, ethyl-vanillin,
eugenol, homovanillic acid, isovanillic acid, isovanillin,
methyl-vanillate, protocatechualdehyde and vanillin). In
parallel, we assessed the toxicity of these compounds on
a stable CHO-K1-derived cell line constitutively express-
ing SEAP [CHO-SEAP18; (51)]. Some of the compounds
were toxic when administered to CHO-SEAP18 cells at
concentrations of 500mM (2-vanillin, eugenol, isovanillin,
methyl-vanillate and protocatechualdehyde), but none of
the 16 tested structures was able to regulate the VACOFF
system. This implies an extraordinary speciﬁcity of
the VACOFF system for vanillic acid (Supplementary
Table S1).
Vanillic acid—transgene expression in mice is mediated by
a food additive
For subsequent applications in functional genomics
research or future gene- and cell-based therapies, it is es-
sential that state-of-the-art gene regulation systems are
functional within entire organisms. To validate the
vanillic acid-controlled gene regulation system in vivo,
we implanted microencapsulated CHO-VAC12 intra-
peritoneally into mice. The treated mice were given a
dose of vanillic acid within the range of 0–500mg/kg
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Figure 4. Characterization of stably transgenic vanillic acid-responsive CHO-K1 cell lines. CHO-K1 was stably co-transfected with pMG250 (PSV40-
VanA1-pA) and pMG252 (P1VanO2-SEAP-pA) and vanillic acid-responsive SEAP expression of the resulting CHO-VAC cell lines was analysed.
(A) After clonal expansion, individual clones were assessed for their vanillic acid-responsive regulation performance. SEAP levels were proﬁled after
cultivation for 48h in the presence and absence of vanillic acid (± VAC). (B) The dose–response proﬁle of CHO-VAC12 was proﬁled after
cultivation for 48h in medium containing increasing concentrations of vanillic acid (0–500mM). (C) SEAP expression kinetics of CHO-VAC12
cultivated for 72h in the presence and absence of 250mM vanillic acid (± VAC). (D) Reversibility of vanillic acid-responsive transgene expression
following periodic addition and removal of the inducer. CHO-VAC12 (80000 cells/ml) were cultivated for 144h in the presence and absence of
250mM vanillic acid (± VAC). Every 48h, the cell density was re-adjusted to 80000 cells/ml and the cells were cultivated in fresh medium with
reversed vanillic acid concentrations.
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treated animals 72h after implantation showed vanillic
acid-dependent dose–response characteristics comparable
to the control experiment using the same batch of
microencapsulated CHO-VAC12 cells exposed to vanillic
acid in an in vitro setting (Figure 5A and B). The serum
SEAP levels of control mice, encapsulated with constitu-
tively expressing CHO-SEAP18, were unresponsive to
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Figure 5. Vanillic acid-controlled SEAP expression in mice. (A) CHO-VAC12 cells were microencapsulated in alginate-poly-(L-lysine)-alginate beads
and implanted intraperitoneally into female OF1 mice (4 10
6cells per mouse). The implanted mice received different concentrations of vanillic acid
twice daily. Seventy-two hours after implantation, the level of SEAP in the serum of the mice was determined. Data represent mean±SEM of 8 mice
per treatment group. (B) SEAP expression proﬁles of the microencapsulated CHO-VAC12 implant batch were cultivated in vitro for 72h at different
vanillic acid concentrations. (C and D) Extracts of wild-type mouse organs were assessed for their vanillic acid content based on their ability to
induce the (C) VACOFF or (D) VACON systems. Vanillic acid-spiked organs were used as positive control. All samples were compared to the effect of
250mM vanillic acid to show the fully induced state of the systems. All extracts were added to CHO-K1 cells transiently transfected with either the
VACON or the VACOFF systems and SEAP expression was assessed after a cultivation period of 48h.
Table 3. Compatibility of vanillic acid-, erythromycin- and tetracycline-responsive transgene control systems
Inducer  Tet / Vac  Tet /+Vac +Tet/ Vac +Tet/+Vac
CHO-VAC12 transfected with the tetracycline-responsive regulation system
Relative SEAP production (%) 100±5.62 2.18±0.31 101.04±6.21 2.07±0.29
Relative SAMY production (%) 100±5.03 99.06±4.53 4.53±0.52 5.01±1.61
Inducer  EM/ Vac  EM/+Vac + EM/ Vac +EM/+Vac
CHO-VAC12 transfected with macrolide-responsive regulation system
Relative SEAP production (%) 100±6.31 2.56±0.09 102.19±7.08 1.95±0.59
Relative SAMY production (%) 100±5.67 98.97±7.73 5.20±0.68 4.83±1.22
CHO-VAC12 were co-transfected with pSAM200 (PSV40-tTA-pA) and pBP99 (PhCMV*-1-SAMY-pA) (A) or pWW35 (PSV40-ET1-pA) and pBP100
(PETR3-SAMY-pA) and grown for 48h in the presence and absence of vanillic acid (Vac, 250mM), erythromycin (EM, 2mg/ml) or tetracycline
(Tet, 2mg/ml) before SEAP and SAMY production was assessed.
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and thus showed similar expression levels as untreated
mice containing CHO-VAC12 implants (0mg/kg vanillic
acid: 15.37±1.57U/l; 500mg/kg vanillic acid:
16.61±1.33U/l). Since vanillic acid is a standard food
additive it may in principle be present in the animal and
interfere with VACOFF-based ﬁne-tuning of transgenes.
We have therefore analysed whether liver, kidney,
muscle and lung tissue extracts of mice kept on a
standard diet could interfere with CHO-K1 cultures en-
gineered for VACOFF- and VACON-controlled SEAP ex-
pression. Unlike positive controls consisting of organ
extracts spiked with vanillic acid, none of the organ
extracts produced from wild-type mice kept on a
standard diet showed any interference with the VACON
or VACOFF systems (Figure 5C and D).
DISCUSSION
Heterologous transgene expression control by non-toxic
small molecule inducers remains one of the major chal-
lenges for future gene- and cell-based therapies as well
as for biopharmaceutical manufacturing of difﬁcult-
to-produce protein therapeutics. The employed inducers
must meet high medical standards and also need to be
physiologically inert for long-term applications in
humans. Antibiotics, steroid hormones, immunosuppres-
sive drugs and a multitude of other regulating molecules
fail to meet these requirements due to their high levels of
side effects, particularly when given over a long period of
time (62–64).
Phenolic acids are a class of compounds that are natur-
ally produced by plants, and are therefore present in vege-
tables and fruits that are widely distributed throughout
human dietary products, like coffee, wine, beer and
vanilla (65). In general, phenolic acids are said to
possess many physiological and pharmacological func-
tions (66) and vanillic acid, in particular, was successfully
evaluated as a suppressor of a potent snake venom (33),
cell apoptosis in Neuro-2A cells (35,36), immune-mediated
liver inﬂammation in mice (37) and carcinogenesis (34).
Being a licensed food additive with a very agreeable
smell (which also enables vanillic acid to be used in fra-
grances), this speciﬁc phenolic acid combines the ideal
properties for functioning as a physiologically inert
inducer molecule in future gene- and cell-based therapies.
This judgment is supported by the reported LD50 value of
5g/kg, which was tested intraperitoneally in rats (67).
Combining the elements of the C. crescentus VanR-
regulated VanAB gene cluster and mammalian transacti-
vation and transsilencing domains, we designed the novel
mammalian heterologous transgene regulation systems
VACON and VACOFF, which respond exclusively to the
licensed food additive vanillic acid. Even closely related
compounds with very similar structure are unable to
regulate the vanillic acid control circuits. The generic
design of the VACOFF system allows for several conﬁgur-
ations using (i) diverse numbers of operators, (ii) different
mammalian transactivation domains and (iii) variable dis-
tances between the speciﬁc operator site and the minimal
promoter, to provide a toolbox for a wide variety of ap-
plications. Due to the high modularity of the VACOFF
system, we were able to provide a speciﬁc conﬁguration
for all of the tested cell types, which exhibited an optimal
regulation performance with high maximal expression and
full reversibility. Furthermore, the VACOFF system
demonstrated interference-free regulation characteristics
when employed in parallel settings with the TETOFF (21)
and the EOFF systems (18). Owing to its unprecedented
speciﬁcity the presented regulation unit is likely to be an
ideal building block for complex synthetic networks
operating with various inducer inputs. The fact that
vanillic acid is a natural plant component, which is
licensed as food additive may facilitate its approval by
governmental agencies for applications in future bio-
pharmaceutical manufacturing scenarios as well as in
gene- and cell-based therapies.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Table 1 and Supplementary Figure 1.
ACKNOWLEDGEMENTS
We thank Ghislaine Charpin-El Hamri and Branka
Roscic for technical assistance and Marcel Tigges as
well as Markus Wieland for critical comments on the
manuscript.
FUNDING
Swiss National Science Foundation (grant no.
31003A0-126022) and in part by the EC Framework 7
(Persist). Funding for open access charge: ETH Zurich.
Conﬂict of interest statement. None declared.
REFERENCES
1. Baumgartel,K., Genoux,D., Welzl,H., Tweedie-Cullen,R.Y.,
Koshibu,K., Livingstone-Zatchej,M., Mamie,C. and Mansuy,I.M.
(2008) Control of the establishment of aversive memory by
calcineurin and Zif268. Nat. Neurosci., 11, 572–578.
2. Gitzinger,M., Parsons,J., Reski,R. and Fussenegger,M. (2009)
Functional cross-kingdom conservation of mammalian and moss
(Physcomitrella patens) transcription, translation and secretion
machineries. Plant Biotechnol. J., 7, 73–86.
3. Ulmer,J.B., Valley,U. and Rappuoli,R. (2006) Vaccine
manufacturing: challenges and solutions. Nat. Biotechnol., 24,
1377–1383.
4. Weber,W. and Fussenegger,M. (2007) Inducible product gene
expression technology tailored to bioprocess engineering.
Curr. Opin. Biotechnol., 18, 399–410.
5. Sharpless,N.E. and Depinho,R.A. (2006) The mighty mouse:
genetically engineered mouse models in cancer drug development.
Nat. Rev. Drug Discov., 5, 741–754.
6. Weber,W., Schoenmakers,R., Keller,B., Gitzinger,M., Grau,T.,
Daoud-El Baba,M., Sander,P. and Fussenegger,M. (2008)
A synthetic mammalian gene circuit reveals antituberculosis
compounds. Proc. Natl Acad. Sci. USA, 105, 9994–9998.
7. Greber,D. and Fussenegger,M. (2007) Mammalian
synthetic biology: engineering of sophisticated gene networks.
J. Biotechnol., 130, 329–345.
PAGE 13 OF 15 Nucleic AcidsResearch, 2012, Vol.40,No. 5 e378. Sanchez-Bustamante,C.D., Kelm,J.M., Mitta,B. and
Fussenegger,M. (2006) Heterologous protein production capacity
of mammalian cells cultivated as monolayers and microtissues.
Biotechnol. Bioeng, 93, 169–180.
9. Weber,W. and Fussenegger,M. (2006) Pharmacologic transgene
control systems for gene therapy. J. Gene Med., 8, 535–556.
10. Deans,T.L., Cantor,C.R. and Collins,J.J. (2007) A tunable genetic
switch based on RNAi and repressor proteins for regulating gene
expression in mammalian cells. Cell, 130, 363–372.
11. Kramer,B.P. and Fussenegger,M. (2005) Hysteresis in a synthetic
mammalian gene network. Proc. Natl Acad. Sci. USA, 102,
9517–9522.
12. Tigges,M., Denervaud,N., Greber,D., Stelling,J. and
Fussenegger,M. (2010) A synthetic low-frequency mammalian
oscillator. Nucleic Acids Res., 38, 2702–2711.
13. Tigges,M., Marquez-Lago,T.T., Stelling,J. and Fussenegger,M.
(2009) A tunable synthetic mammalian oscillator. Nature, 457,
309–312.
14. Gersbach,C.A., Le Doux,J.M., Guldberg,R.E. and Garcia,A.J.
(2006) Inducible regulation of Runx2-stimulated osteogenesis.
Gene Ther., 13, 873–882.
15. Kemmer,C., Gitzinger,M., Daoud-El Baba,M., Djonov,V.,
Stelling,J. and Fussenegger,M. (2010) Self-sufﬁcient control of
urate homeostasis in mice by a synthetic circuit. Nat. Biotechnol.,
28, 355–360.
16. Ehrbar,M., Schoenmakers,R., Christen,E.H., Fussenegger,M. and
Weber,W. (2008) Drug-sensing hydrogels for the inducible release
of biopharmaceuticals. Nat. Mater., 7, 800–804.
17. Urlinger,S., Helbl,V., Guthmann,J., Pook,E., Grimm,S. and
Hillen,W. (2000) The p65 domain from NF-kappaB is an efﬁcient
human activator in the tetracycline-regulatable gene expression
system. Gene, 247, 103–110.
18. Weber,W., Fux,C., Daoud-el Baba,M., Keller,B., Weber,C.C.,
Kramer,B.P., Heinzen,C., Aubel,D., Bailey,J.E. and
Fussenegger,M. (2002) Macrolide-based transgene control
in mammalian cells and mice. Nat. Biotechnol., 20,
901–907.
19. Weber,W., Kramer,B.P., Fux,C., Keller,B. and Fussenegger,M.
(2002) Novel promoter/transactivator conﬁgurations for
macrolide- and streptogramin-responsive transgene expression in
mammalian cells. J. Gene Med., 4, 676–686.
20. Fussenegger,M., Morris,R.P., Fux,C., Rimann,M., von
Stockar,B., Thompson,C.J. and Bailey,J.E. (2000)
Streptogramin-based gene regulation systems for mammalian cells.
Nat. Biotechnol., 18, 1203–1208.
21. Gossen,M. and Bujard,H. (1992) Tight control of gene
expression in mammalian cells by tetracycline-responsive
promoters. Proc. Natl Acad. Sci. USA, 89, 5547–5551.
22. Gossen,M., Freundlieb,S., Bender,G., Muller,G., Hillen,W. and
Bujard,H. (1995) Transcriptional activation by tetracyclines in
mammalian cells. Science, 268, 1766–1769.
23. Neddermann,P., Gargioli,C., Muraglia,E., Sambucini,S.,
Bonelli,F., De Francesco,R. and Cortese,R. (2003) A novel,
inducible, eukaryotic gene expression system based on the
quorum-sensing transcription factor TraR. EMBO Rep., 4,
159–165.
24. Weber,W., Rimann,M., Spielmann,M., Keller,B., Daoud-El
Baba,M., Aubel,D., Weber,C.C. and Fussenegger,M. (2004)
Gas-inducible transgene expression in mammalian cells and mice.
Nat. Biotechnol., 22, 1440–1444.
25. Hartenbach,S., Daoud-El Baba,M., Weber,W. and
Fussenegger,M. (2007) An engineered L-arginine sensor of
Chlamydia pneumoniae enables arginine-adjustable transcription
control in mammalian cells and mice. Nucleic Acids Res., 35,
e136.
26. Weber,W., Bacchus,W., Daoud-El Baba,M. and Fussenegger,M.
(2007) Vitamin H-regulated transgene expression in mammalian
cells. Nucleic Acids Res., 35, e116.
27. Weber,W., Lienhart,C., Daoud-El Baba,M. and Fussenegger,M.
(2009) A Biotin-triggered genetic switch in mammalian cells and
mice. Metab. Eng, 11, 117–124.
28. Gitzinger,M., Kemmer,C., El-Baba,M.D., Weber,W. and
Fussenegger,M. (2009) Controlling transgene expression in
subcutaneous implants using a skin lotion containing the apple
metabolite phloretin. Proc. Natl Acad. Sci. USA, 106,
10638–10643.
29. Sinha,A.K., Sharma,U.K. and Sharma,N. (2008) A comprehensive
review on vanilla ﬂavor: extraction, isolation and quantiﬁcation
of vanillin and others constituents. Int. J. Food Sci. Nutr., 59,
299–326.
30. Sostaric,T., Boyce,M.C. and Spickett,E.E. (2000) Analysis of the
volatile components in vanilla extracts and ﬂavorings by
solid-phase microextraction and gas chromatography.
J. Agric. Food Chem., 48, 5802–5807.
31. Huang,W.Y. and Sheu,S.J. (2006) Separation and identiﬁcation of
the organic acids in Angelicae Radix and Ligustici Rhizoma by
HPLC and CE. J. Sep. Sci., 29, 2616–2624.
32. Dhananjaya,B.L., Nataraju,A., Raghavendra Gowda,C.D.,
Sharath,B.K. and D’Souza,C.J. (2009) Vanillic acid as a novel
speciﬁc inhibitor of snake venom 50-nucleotidase: a
pharmacological tool in evaluating the role of the enzyme in
snake envenomation. Biochemistry, 74, 1315–1319.
33. Dhananjaya,B.L., Nataraju,A., Rajesh,R., Raghavendra
Gowda,C.D., Sharath,B.K., Vishwanath,B.S. and D’Souza,C.J.
(2006) Anticoagulant effect of Naja naja venom 5’nucleotidase:
demonstration through the use of novel speciﬁc inhibitor, vanillic
acid. Toxicon, 48, 411–421.
34. Vetrano,A.M., Heck,D.E., Mariano,T.M., Mishin,V., Laskin,D.L.
and Laskin,J.D. (2005) Characterization of the oxidase activity in
mammalian catalase. J. Biol. Chem., 280, 35372–35381.
35. Huang,S.M., Chuang,H.C., Wu,C.H. and Yen,G.C. (2008)
Cytoprotective effects of phenolic acids on methylglyoxal-induced
apoptosis in Neuro-2A cells. Mol. Nutr. Food Res., 52, 940–949.
36. Huang,S.M., Hsu,C.L., Chuang,H.C., Shih,P.H., Wu,C.H. and
Yen,G.C. (2008) Inhibitory effect of vanillic acid on
methylglyoxal-mediated glycation in apoptotic Neuro-2A cells.
Neurotoxicology, 29, 1016–1022.
37. Itoh,A., Isoda,K., Kondoh,M., Kawase,M., Kobayashi,M.,
Tamesada,M. and Yagi,K. (2009) Hepatoprotective effect of
syringic acid and vanillic acid on concanavalin a-induced liver
injury. Biol. Pharm. Bull., 32, 1215–1219.
38. Pietta,P.G., Simonetti,P., Gardana,C., Brusamolino,A.,
Morazzoni,P. and Bombardelli,E. (1998) Catechin metabolites
after intake of green tea infusions. Biofactors, 8, 111–118.
39. Boerjan,W., Ralph,J. and Baucher,M. (2003) Lignin biosynthesis.
Annu. Rev. Plant Biol., 54, 519–546.
40. Martinez,A.T., Speranza,M., Ruiz-Duenas,F.J., Ferreira,P.,
Camarero,S., Guillen,F., Martinez,M.J., Gutierrez,A. and del
Rio,J.C. (2005) Biodegradation of lignocellulosics: microbial,
chemical, and enzymatic aspects of the fungal attack of lignin.
Int. Microbiol., 8, 195–204.
41. Poindexter,J.S. (1964) Biological properties and classiﬁcation of
the caulobacter group. Bacteriol. Rev., 28, 231–295.
42. Harwood,C.S. and Parales,R.E. (1996) The beta-ketoadipate
pathway and the biology of self-identity. Annu. Rev. Microbiol.,
50, 553–590.
43. Thanbichler,M., Iniesta,A.A. and Shapiro,L. (2007)
A comprehensive set of plasmids for vanillate- and
xylose-inducible gene expression in Caulobacter crescentus.
Nucleic Acids Res., 35, e137.
44. Brunel,F. and Davison,J. (1988) Cloning and sequencing of
Pseudomonas genes encoding vanillate demethylase. J. Bacteriol.,
170, 4924–4930.
45. Merkens,H., Beckers,G., Wirtz,A. and Burkovski,A. (2005)
Vanillate metabolism in Corynebacterium glutamicum. Curr.
Microbiol., 51, 59–65.
46. Nishimura,M., Ishiyama,D. and Davies,J. (2006) Molecular
cloning of streptomyces genes encoding vanillate demethylase.
Biosci. Biotechnol. Biochem., 70, 2316–2319.
47. Segura,A., Bunz,P.V., D’Argenio,D.A. and Ornston,L.N. (1999)
Genetic analysis of a chromosomal region containing vanA and
vanB, genes required for conversion of either ferulate or vanillate
to protocatechuate in Acinetobacter. J. Bacteriol., 181, 3494–3504.
48. Greber,D. and Fussenegger,M. (2007) Multi-gene engineering:
simultaneous expression and knockdown of six genes off a single
platform. Biotechnol. Bioeng, 96, 821–834.
49. Berger,J., Hauber,J., Hauber,R., Geiger,R. and Cullen,B.R. (1988)
Secreted placental alkaline phosphatase: a powerful new
e37 Nucleic Acids Research, 2012,Vol. 40,No. 5 PAGE 14 OF 15quantitative indicator of gene expression in eukaryotic cells. Gene,
66, 1–10.
50. Schlatter,S., Rimann,M., Kelm,J. and Fussenegger,M. (2002)
SAMY, a novel mammalian reporter gene derived from Bacillus
stearothermophilus alpha-amylase. Gene, 282, 19–31.
51. Fluri,D.A., Kemmer,C., Daoud-El Baba,M. and Fussenegger,M.
(2008) A novel system for trigger-controlled drug release from
polymer capsules. J. Control Release, 131, 211–219.
52. Moosmann,P., Georgiev,O., Thiesen,H.J., Hagmann,M. and
Schaffner,W. (1997) Silencing of RNA polymerases II and
III-dependent transcription by the KRAB protein domain of
KOX1, a Kruppel-type zinc ﬁnger factor. Biol. Chem., 378,
669–677.
53. Ayyanathan,K., Lechner,M.S., Bell,P., Maul,G.G., Schultz,D.C.,
Yamada,Y., Tanaka,K., Torigoe,K. and Rauscher,F.J. 3rd (2003)
Regulated recruitment of HP1 to a euchromatic gene
induces mitotically heritable, epigenetic gene silencing: a
mammalian cell culture model of gene variegation. Genes Dev.,
17, 1855–1869.
54. Peng,H., Ivanov,A.V., Oh,H.J., Lau,Y.F. and Rauscher,F.J. 3rd
(2009) Epigenetic gene silencing by the SRY protein is mediated
by a KRAB-O protein that recruits the KAP1 co-repressor
machinery. J. Biol. Chem., 284, 35670–35680.
55. Malphettes,L., Weber,C.C., El-Baba,M.D., Schoenmakers,R.G.,
Aubel,D., Weber,W. and Fussenegger,M. (2005) A novel
mammalian expression system derived from components
coordinating nicotine degradation in arthrobacter nicotinovorans
pAO1. Nucleic Acids Res., 33, e107.
56. Weber,W. and Fussenegger,M. (2002) Artiﬁcial mammalian gene
regulation networks-novel approaches for gene therapy and
bioengineering. J. Biotechnol., 98, 161–187.
57. Muller,J., Oehler,S. and Muller-Hill,B. (1996) Repression of lac
promoter as a function of distance, phase and quality of an
auxiliary lac operator. J. Mol. Biol., 257, 21–29.
58. Sathya,G., Li,W., Klinge,C.M., Anolik,J.H., Hilf,R. and
Bambara,R.A. (1997) Effects of multiple estrogen responsive
elements, their spacing, and location on estrogen response of
reporter genes. Mol. Endocrinol., 11, 1994–2003.
59. Becskei,A., Kaufmann,B.B. and van Oudenaarden,A. (2005)
Contributions of low molecule number and chromosomal
positioning to stochastic gene expression. Nat. Genet., 37,
937–944.
60. Kramer,B.P., Viretta,A.U., Daoud-El-Baba,M., Aubel,D.,
Weber,W. and Fussenegger,M. (2004) An engineered epigenetic
transgene switch in mammalian cells. Nat. Biotechnol., 22,
867–870.
61. Tigges,M. and Fussenegger,M. (2009) Recent advances in
mammalian synthetic biology-design of synthetic transgene control
networks. Curr. Opin. Biotechnol., 20, 449–460.
62. Kuypers,D.R. (2005) Beneﬁt-risk assessment of sirolimus in renal
transplantation. Drug Saf., 28, 153–181.
63. Sanchez,A.R., Rogers,R.S. 3rd and Sheridan,P.J. (2004)
Tetracycline and other tetracycline-derivative staining of the teeth
and oral cavity. Int. J. Dermatol., 43, 709–715.
64. Wurm,F.M. (2004) Production of recombinant protein therapeutics
in cultivated mammalian cells. Nat. Biotechnol., 22, 1393–1398.
65. Stalikas,C.D. (2008) Phenolic acids and ﬂavonoids: occurrence
and analytical methods. Methods Mol. Biol., 610, 65–90.
66. Nardini,M., Pisu,P., Gentili,V., Natella,F., Di Felice,M.,
Piccolella,E. and Scaccini,C. (1998) Effect of caffeic acid on
tert-butyl hydroperoxide-induced oxidative stress in U937. Free
Radic. Biol. Med., 25, 1098–1105.
67. Comptes Rendus Hebdomadaires des Seances. (1956) Academie
des Sciences, Vol. 243, 609.
68. Moser,S., Rimann,M., Fux,C., Schlatter,S., Bailey,J.E. and
Fussenegger,M. (2001) Dual-regulated expression technology: a
new era in the adjustment of heterologous gene expression in
mammalian cells. J. Gene Med., 3, 529–549.
69. Fussenegger,M., Moser,S., Mazur,X. and Bailey,J.E. (1997)
Autoregulated multicistronic expression vectors provide one-step
cloning of regulated product gene expression in mammalian cells.
Biotechnol. Prog., 13, 733–740.
PAGE 15 OF 15 Nucleic AcidsResearch, 2012, Vol.40,No. 5 e37